Jinhe Biotechnology CO., LTD.

SZSE:002688 Rapporto sulle azioni

Cap. di mercato: CN¥3.3b

Jinhe Biotechnology Performance dei guadagni passati

Il passato criteri di controllo 4/6

Jinhe Biotechnology's earnings have been declining at an average annual rate of -19.3%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 5% per year. Jinhe Biotechnology's return on equity is 3.7%, and it has net margins of 4.3%.

Informazioni chiave

-19.3%

Tasso di crescita degli utili

-25.2%

Tasso di crescita dell'EPS

Pharmaceuticals Crescita del settore10.9%
Tasso di crescita dei ricavi5.0%
Rendimento del capitale proprio3.7%
Margine netto4.3%
Ultimo aggiornamento sui guadagni30 Sep 2024

Aggiornamenti sulle prestazioni recenti

Recent updates

Jinhe Biotechnology (SZSE:002688) Is Due To Pay A Dividend Of CN¥0.10

May 27
Jinhe Biotechnology (SZSE:002688) Is Due To Pay A Dividend Of CN¥0.10

Subdued Growth No Barrier To Jinhe Biotechnology CO., LTD. (SZSE:002688) With Shares Advancing 26%

May 13
Subdued Growth No Barrier To Jinhe Biotechnology CO., LTD. (SZSE:002688) With Shares Advancing 26%

Jinhe Biotechnology CO., LTD. (SZSE:002688) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

May 13
Jinhe Biotechnology CO., LTD. (SZSE:002688) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Ripartizione dei ricavi e delle spese

Come Jinhe Biotechnology guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storia dei guadagni e delle entrate

SZSE:002688 Ricavi, spese e utili (CNY Millions )
DataRicaviGuadagniSpese G+ASpese di R&S
30 Sep 242,2629738085
30 Jun 242,2078838280
31 Mar 242,1669537978
31 Dec 232,1748637474
30 Sep 232,0607639172
30 Jun 232,0307837675
31 Mar 232,1308136378
01 Jan 232,1237635482
30 Sep 222,2728632978
30 Jun 222,2427832876
31 Mar 222,1365631574
01 Jan 222,0789431872
30 Sep 212,04612631670
30 Jun 211,92712531069
31 Mar 211,84413331869
31 Dec 201,81511730966
30 Sep 201,74114430963
30 Jun 201,79717530162
31 Mar 201,83120130356
31 Dec 191,78218530561
30 Sep 191,76717832760
30 Jun 191,75918333951
31 Mar 191,67617133150
31 Dec 181,62916431641
30 Sep 181,60313831937
30 Jun 181,52111727354
31 Mar 181,4579827543
31 Dec 171,45810827534
30 Sep 171,41414024221
30 Jun 171,4401472720
31 Mar 171,4861552660
31 Dec 161,4961642550
30 Sep 161,4501592370
30 Jun 161,3961482230
31 Mar 161,3151322010
31 Dec 151,2501051920
30 Sep 151,143841820
30 Jun 151,030791540
31 Mar 15956801440
31 Dec 14840771420
30 Sep 14771871410
30 Jun 14765951330
31 Mar 14756931320
31 Dec 13741901260

Guadagni di qualità: 002688 has high quality earnings.

Margine di profitto in crescita: 002688's current net profit margins (4.3%) are higher than last year (3.7%).

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: 002688's earnings have declined by 19.3% per year over the past 5 years.

Accelerare la crescita: 002688's earnings growth over the past year (27.5%) exceeds its 5-year average (-19.3% per year).

Guadagni vs Settore: 002688 earnings growth over the past year (27.5%) exceeded the Pharmaceuticals industry -1.2%.

Rendimento del capitale proprio

ROE elevato: 002688's Return on Equity (3.7%) is considered low.

Rendimento delle attività

Rendimento del capitale investito

Scoprire le aziende con forti performance passate

7D

1Y

7D

1Y

7D

1Y